Mangalam Drugs Reports Decline in Sales and Profitability Amid Operational Challenges in June 2025

Mangalam Drugs and Organics has reported its financial results for the quarter ending June 2025, revealing significant challenges within its operations. The company's net sales for the quarter stood at Rs 57.35 crore, reflecting a notable decline compared to the average of Rs 79.56 crore over the previous four quarters. This downturn indicates a concerning trend in sales performance. Additionally, the profit before tax less other income (PBT) has shown a drastic shift, recorded at Rs -13.00 crore, which is substantially lower than the average PBT of Rs 1.07 crore from the last four quarters. This suggests a significant deterioration in profitability. The operating profit margin has also reached its lowest point in five quarters at -7.79%, indicating challenges in operational efficiency. Furthermore, the earnings per share (EPS) have declined to Rs -8.72, highlighting a reduction in profitability for shareholders. In light of these developments, Mangalam Drugs has experienced an adjustment in its evaluation, with its score reflecting these adverse financial trends. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.